share_log

UBS Maintains Neutral on 10x Genomics, Lowers Price Target to $20

Benzinga ·  Oct 30, 2024 22:25  · Ratings

UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:TXG) with a Neutral and lowers the price target from $25 to $20.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment